CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

All Catalyst Types

Phase 2 Clinical Trials

As of Nov 17, 2026, CatalystAlert tracks 918 upcoming phase 2 clinical trials: 2 with the exact day known, the rest estimated by month from sources such as ClinicalTrials.gov and company filings. Next up: AZN, RHHBY, SKYE.

Mid-stage trials that test whether a drug actually works (efficacy) and at what dose, in a few dozen to a few hundred patients.

These dates are public. The filterable calendar, alerts, exports and AI research are in the app — free account: the next 7 days and 3 companies you track. Plans →

918 UpcomingView Full Calendar

November 202619

Nov '26
AZNPhase 2

AZD0901 Phase 2 Est. Readout

AZD0901
Nov 2026~
CT.gov
00%
Nov '26
RHHBYPhase 2

RO7269162 Phase 2 Est. Readout

RO7269162
Nov 2026~
CT.gov
00%
Nov '26
SKYEPhase 2

Nimacimab injection Phase 2 Est. Readout (CBeyond)

Nimacimab injection
Nov 2026~
CT.gov
00%
Nov '26
INCYPhase 2

povorcitinib Phase 2 Est. Readout

Povorcitinib
Nov 2026~
CT.gov
00%
Nov '26
GSKPhase 2

Dostarlimab Phase 2 Est. Readout

Dostarlimab
Nov 2026~
CT.gov
00%
Nov '26
TECXPhase 2

TX000045- Dose A Phase 2 Est. Readout

TX000045- Dose A
Nov 2026~
CT.gov
00%
Nov '26
BIOAPhase 2

Oral BGE-102 Phase 2 Est. Readout (QUELL-CV)

Oral BGE-102
Nov 2026~
CT.gov
00%
Nov '26
IMCRPhase 2

IMC-R117C Phase 2 Est. Readout

IMC-R117C
Nov 2026~
CT.gov
00%
Nov '26
TXMDPhase 2

RNK08954 Phase 2 Est. Readout

RNK08954
Nov 2026~
CT.gov
00%
Nov '26
AZNPhase 2

Tremelimumab Phase 2 Est. Readout

Tremelimumab
Nov 2026~
CT.gov
00%
Nov '26
VTRSPhase 2

MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) Phase 2 Est. Readout

MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)
Nov 2026~
CT.gov
00%
Nov '26
AMGNPhase 2

Anvumetostat Phase 2 Est. Readout

Anvumetostat
Nov 2026~
CT.gov
00%
Nov '26
MRNAPhase 2

mRNA-3745 Phase 2 Est. Readout

mRNA-3745
Nov 2026~
CT.gov
00%
Nov '26
BAVA.COPhase 2

MVA-BN (Quail) Phase 2 Est. Readout

MVA-BN (Quail)
Nov 2026~
CT.gov
00%
Nov '26
AURAPhase 2

AU-011 Phase 2 Est. Readout

AU-011
Nov 2026~
CT.gov
00%
Nov '26
NTHIPhase 2

Perillyl alcohol Phase 2 Est. Readout

Perillyl alcohol
Nov 2026~
CT.gov
00%
Nov '26
TAKPhase 2

TAK-360 Phase 2 Est. Readout

TAK-360
Nov 2026~
CT.gov
00%
Nov '26
IVBXFPhase 2

IBI363 Phase 2 Est. Readout

IBI363
Nov 2026~
CT.gov
00%
Nov '26
ARVNPhase 2

ARV-806 Phase 2 Est. Readout

ARV-806
Nov 2026~
CT.gov
00%

December 202681

Dec '26
AXSMPhase 2

Solriamfetol Phase 2 Est. Readout (SOLARIMS)

Solriamfetol
Dec 2026~
CT.gov
00%
Dec '26
RHHBYPhase 2

tocilizumab Phase 2 Est. Readout

tocilizumab
Dec 2026~
CT.gov
00%
Dec '26
AZNPhase 2

Acalabrutinib Phase 2 Est. Readout

Acalabrutinib
Dec 2026~
CT.gov
00%
Dec '26
SNYPhase 2

Pandemic flu H5 HA mRNA SD2 vaccine Phase 2 Est. Readout

Pandemic flu H5 HA mRNA SD2 vaccine
Dec 2026~
CT.gov
00%
Dec '26
PFEPhase 2

elranatamab Phase 2 Est. Readout

elranatamab
Dec 2026~
CT.gov
00%
Dec '26
RCUSPhase 2

Quemliclustat Phase 2 Est. Readout (SBRT-AMICO)

Quemliclustat
Dec 2026~
CT.gov
00%
Dec '26
MRKPhase 2

Axatilimab Phase 2 Est. Readout

Axatilimab
Dec 2026~
CT.gov
00%
Dec '26
GILDPhase 2

Sacituzumab Govitecan (SG) Phase 2 Est. Readout

Sacituzumab Govitecan (SG)
Dec 2026~
CT.gov
00%
Dec '26
ZNTLPhase 2

azenosertib Phase 2 Est. Readout (DENALI)

azenosertib
Dec 2026~
CT.gov
00%
Dec '26
NVSPhase 2

177Lu-PSMA-617 Phase 2 Est. Readout

177Lu-PSMA-617
Dec 2026~
CT.gov
00%
Dec '26
KZIAPhase 2

PAXALISIB Phase 2 Est. Readout

PAXALISIB
Dec 2026~
CT.gov
00%
Dec '26
RNACPhase 2

Descartes-08 Phase 2 Est. Readout (SLE-001)

Descartes-08
Dec 2026~
CT.gov
00%
Dec '26
JHPCYPhase 2

Camrelizumab plus apatinib CohortA Phase 2 Est. Readout

Camrelizumab plus apatinib CohortA
Dec 2026~
CT.gov
00%
Dec '26
ONCPhase 2

Zanubrutinib Phase 2 Est. Readout (ZEBRA)

Zanubrutinib
Dec 2026~
CT.gov
00%
Dec '26
SNDXPhase 2

SNDX-5613 Phase 2 Est. Readout

SNDX-5613
Dec 2026~
CT.gov
00%
Dec '26
ABUSPhase 2

Imdusiran (AB-729) Phase 2 Est. Readout (i-LIVER)

Imdusiran (AB-729)
Dec 2026~
CT.gov
00%
Dec '26
LLYPhase 2

Abemaciclib Phase 2 Est. Readout

Abemaciclib
Dec 2026~
CT.gov
00%
Dec '26
LLYPhase 2

Necitumumab Phase 2 Est. Readout

Necitumumab
Dec 2026~
CT.gov
00%
Dec '26
REGNPhase 2

REGN7999 Phase 2 Est. Readout (FERVENT-1)

REGN7999
Dec 2026~
CT.gov
00%
Dec '26
NVSPhase 2

Abiraterone Phase 2 Est. Readout

JSB462
Dec 2026~
CT.gov
00%
Dec '26
ESALYPhase 2

Lecanemab Phase 2 Est. Readout

Lecanemab
Dec 2026~
CT.gov
00%
Dec '26
PFEPhase 2

Sunitinib Phase 2 Est. Readout

Sunitinib
Dec 2026~
CT.gov
00%
Dec '26
MRKPhase 2

Pembrolizumab Phase 2 Est. Readout

pembrolizumab
Dec 2026~
CT.gov
00%
Dec '26
PFEPhase 2

Ritlecitinib Phase 2 Est. Readout

Ritlecitinib
Dec 2026~
CT.gov
00%
Dec '26
AZNPhase 2

Baxdrostat/dapagliflozin Phase 2 Est. Readout

Baxdrostat/dapagliflozin
Dec 2026~
CT.gov
00%
Dec '26
MRKPhase 2

pembrolizumab Phase 2 Est. Readout

pembrolizumab
Dec 2026~
CT.gov
00%
Dec '26
PFEPhase 2

disitamab vedotin Phase 2 Est. Readout

disitamab vedotin
Dec 2026~
CT.gov
00%
Dec '26
GSKPhase 2

MMB Phase 2 Est. Readout

MMB
Dec 2026~
CT.gov
00%
4w
MBRXPhase 2

Phase 2 Results - Annamycin

Dec 12
Source
00%
Dec '26
NVOPhase 2

NNC0662-0419 Phase 2 Est. Readout

NNC0662-0419
Dec 2026~
CT.gov
00%
Dec '26
PHATPhase 2

Vonoprazan Phase 2 Est. Readout

Vonoprazan
Dec 2026~
CT.gov
00%
Dec '26
ENTAPhase 2

zelicapavir Phase 2 Est. Readout

zelicapavir
Dec 2026~
CT.gov
00%
Dec '26
KRYSPhase 2

KB801 Phase 2 Est. Readout (EMERALD-1)

KB801
Dec 2026~
CT.gov
00%
Dec '26
TARAPhase 2

TARA-002 Phase 2 Est. Readout (STARBORN-1)

TARA-002
Dec 2026~
CT.gov
00%
Dec '26
GEHCPhase 2

Regadenoson Phase 2 Est. Readout

Regadenoson
Dec 2026~
CT.gov
00%
Dec '26
ESALYPhase 2

Lenvatinib Phase 2 Est. Readout

Lenvatinib
Dec 2026~
CT.gov
00%
Dec '26
MOLNPhase 2

PMD-026 Phase 2 Est. Readout

PMD-026
Dec 2026~
CT.gov
00%
Dec '26
KPTIPhase 2

Selinexor Phase 2 Est. Readout

Selinexor
Dec 2026~
CT.gov
00%
Dec '26
DSGNPhase 2

DT-216P2 Phase 2 Est. Readout

DT-216P2
Dec 2026~
CT.gov
00%
Dec '26
REGNPhase 2

Cemiplimab Phase 2 Est. Readout

cemiplimab
Dec 2026~
CT.gov
00%
Dec '26
GSKPhase 2

Niraparib Phase 2 Est. Readout (RAISE)

Niraparib
Dec 2026~
CT.gov
00%
Dec '26
KRROPhase 2

KRRO-110 Phase 2 Est. Readout

KRRO-110
Dec 2026~
CT.gov
00%
Dec '26
CORTPhase 2

relacorilant Phase 2 Est. Readout

Relacorilant
Dec 2026~
CT.gov
00%
Dec '26
CRDFPhase 2

Onvansertib Phase 2 Est. Readout

Onvansertib
Dec 2026~
CT.gov
00%
Dec '26
AVLNPhase 2

AP02 Phase 2 Est. Readout (AURA-IPF)

AP02
Dec 2026~
CT.gov
00%
Dec '26
RCUSPhase 2

Etrumadenant (AB928) Phase 2 Est. Readout (PANTHER)

Etrumadenant (AB928)
Dec 2026~
CT.gov
00%
Dec '26
DWTXPhase 2

Halneuron Phase 2 Est. Readout

Halneuron
Dec 2026~
CT.gov
00%
Dec '26
EPRXPhase 2

EP-104GI Phase 2 Est. Readout (RESOLVE)

EP-104GI
Dec 2026~
CT.gov
00%
Dec '26
AAPGPhase 2

APG2575 Phase 2 Est. Readout

APG2575
Dec 2026~
CT.gov
00%
Dec '26
ABBVPhase 2

ABBV-400 Phase 2 Est. Readout

ABBV-400
Dec 2026~
CT.gov
00%
Dec '26
JAZZPhase 2

CPX-351 Phase 2 Est. Readout

CPX-351
Dec 2026~
CT.gov
00%
Dec '26
IPN.PAPhase 2

Association of pembrolizumab + cabozantinib Phase 2 Est. Readout (PEMBROCABOSARC)

Association of pembrolizumab + cabozantinib
Dec 2026~
CT.gov
00%
Dec '26
ARDXPhase 2

Tenapanor Phase 2 Est. Readout

Tenapanor
Dec 2026~
CT.gov
00%
Dec '26
ABVXPhase 2

Obefazimod Phase 2 Est. Readout (ENHANCE-CD)

Obefazimod
Dec 2026~
CT.gov
00%
Dec '26
JHPCYPhase 2

HRS-5041 tablets Phase 2 Est. Readout

HRS-5041 tablets
Dec 2026~
CT.gov
00%
Dec '26
OMERPhase 2

OMS906 study drug Phase 2 Est. Readout

OMS906 study drug
Dec 2026~
CT.gov
00%
Dec '26
LLYPhase 2

Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide Phase 2 Est. Readout

Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
Dec 2026~
CT.gov
00%
Dec '26
RHHBYPhase 2

Association atezolizumab + BDB001 + RT Phase 2 Est. Readout (AGADIR)

Association atezolizumab + BDB001 + RT
Dec 2026~
CT.gov
00%
Dec '26
DNLIPhase 2

DNL593 Phase 2 Est. Readout

DNL593
Dec 2026~
CT.gov
00%
Dec '26
TAKPhase 2

Ixazomib Phase 2 Est. Readout

Ixazomib
Dec 2026~
CT.gov
00%
Dec '26
ANROPhase 2

ALTO-300 Phase 2 Est. Readout

ALTO-300
Dec 2026~
CT.gov
00%
Dec '26
MRKPhase 2

Infliximab Phase 2 Est. Readout (RAPID-I)

Infliximab
Dec 2026~
CT.gov
00%
Dec '26
SOBI.STPhase 2

Palifermin Phase 2 Est. Readout

palifermin
Dec 2026~
CT.gov
00%
Dec '26
AIMPhase 2

Rintatolimod Phase 2 Est. Readout (DURIPANC)

Rintatolimod
Dec 2026~
CT.gov
00%
Dec '26
ALPMYPhase 2

ZEN003694 Phase 2 Est. Readout

ZEN003694
Dec 2026~
CT.gov
00%
Dec '26
ABTPhase 2

Modified FOLFIRINOX Phase 2 Est. Readout

Modified FOLFIRINOX
Dec 2026~
CT.gov
00%
Dec '26
TXMDPhase 2

TH9619 Phase 2 Est. Readout

TH9619
Dec 2026~
CT.gov
00%
Dec '26
HRTXPhase 2

F18 FBPA Injection Phase 2 Est. Readout

F18 FBPA Injection
Dec 2026~
CT.gov
00%
Dec '26
GLUEPhase 2

Oral MRT-2359 Phase 2 Est. Readout

Oral MRT-2359
Dec 2026~
CT.gov
00%
Dec '26
YMABPhase 2

Hu3F8 With GM-CSF Phase 2 Est. Readout

Hu3F8 With GM-CSF
Dec 2026~
CT.gov
00%
Dec '26
BMYPhase 2

Elotuzumab Phase 2 Est. Readout

Elotuzumab
Dec 2026~
CT.gov
00%
Dec '26
INABPhase 2

Autologous genetically modified gamma-delta T cells Phase 2 Est. Readout

Autologous genetically modified gamma-delta T cells
Dec 2026~
CT.gov
00%
Dec '26
DNTHPhase 2

Claseprubart Phase 2 Est. Readout (MOMENTUM)

Claseprubart
Dec 2026~
CT.gov
00%
Dec '26
EIKNPhase 2

EIK1001 Phase 2 Est. Readout

EIK1001
Dec 2026~
CT.gov
00%
Dec '26
INCYPhase 2

Axatilimab Phase 2 Est. Readout (NAHL)

Axatilimab
Dec 2026~
CT.gov
00%
Dec '26
GNLXPhase 2

Olvi-Vec Phase 2 Est. Readout

Olvi-Vec
Dec 2026~
CT.gov
00%
Dec '26
BAYRYPhase 2

Association of darolutamide and EBRT Phase 2 Est. Readout (DARIUS)

Association of darolutamide and EBRT
Dec 2026~
CT.gov
00%
Dec '26
PFEPhase 2

Tucatinib Oral Tablet Phase 2 Est. Readout (ETIC-LM)

Tucatinib Oral Tablet
Dec 2026~
CT.gov
00%
Dec '26
GRFSPhase 2

Albumin infusion (albumin) Phase 2 Est. Readout

Albumin infusion (albumin)
Dec 2026~
CT.gov
00%
Dec '26
IMMXPhase 2

NXC-201 CAR-T Phase 2 Est. Readout (NEXICART-2)

NXC-201 CAR-T
Dec 2026~
CT.gov
00%
Dec '26
IRLAPhase 2

LAM-001 Phase 2 Est. Readout (INSPO-BOS)

LAM-001
Dec 2026~
CT.gov
00%
Get Phase 2 Clinical Trials Alerts

About Phase 2 Clinical Trials

Phase 2 clinical trials are mid-stage studies — usually dozens to a few hundred patients — designed to establish proof of concept: does the drug produce a clinical effect, at what dose, and with what side-effect profile? They bridge the safety-focused Phase 1 and the confirmatory Phase 3.

Because Phase 2 is the first real test of efficacy in patients with the target disease, its readouts are often the highest-information catalyst in a young company’s life — the moment the market first learns whether the science translates.

Why Phase 2 Trials matter to investors

Phase 2 is statistically the hardest hurdle in drug development — more programs fail here than at any other stage. A clean Phase 2 readout can transform a micro-cap’s valuation and attract partners; a miss frequently ends the program. That asymmetry makes Phase 2 dates a core watch-list catalyst.

Frequently asked questions

What is a Phase 2 clinical trial?

A Phase 2 trial is a mid-stage study in dozens to a few hundred patients that tests whether a drug is effective and identifies the right dose, after Phase 1 established basic safety.

Why are Phase 2 results so important?

Phase 2 is the first genuine test of efficacy in the target disease and has the highest failure rate of any phase, so its readout carries the most new information for investors.

What comes after a successful Phase 2 trial?

Positive Phase 2 data typically leads to an end-of-Phase-2 meeting with the FDA and the design of pivotal Phase 3 trials — and often a financing or partnership.